Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03539822
Recruitment Status : Recruiting
First Posted : May 29, 2018
Last Update Posted : May 10, 2022
Sponsor:
Collaborators:
AstraZeneca
Exelixis
Information provided by (Responsible Party):
Anwaar Saeed, University of Kansas Medical Center

Brief Summary:
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at safety, tolerability and efficacy endpoints.

Condition or disease Intervention/treatment Phase
Gastric Cancer Esophageal Adenocarcinoma Hepatocellular Carcinoma Colorectal Cancer Drug: Cabozantinib Drug: Durvalumab Drug: Tremelimumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 117 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Phase II has 4 disease cohorts, the first 3 with 29 patients each, the 4th for advanced HCC patients with 24 patients and will be preceded by a safety lead in of 6-9 patients.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)
Actual Study Start Date : October 22, 2018
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : June 30, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cabozantinib plus Durvalumab (Gastric & esophageal cancer cohort)

Cabozantinib

  • By mouth (PO) once daily on days 1-28 of every 28 day cycle
  • Dose will be 40mg

Durvalumab

*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle

Drug: Cabozantinib
by mouth
Other Name: multi-tyrosine kinase Inhibitor

Drug: Durvalumab
infusion
Other Name: anti-Programmed cell death protein 1 (PD-L1) inhibitor

Experimental: Cabozantinib plus Durvalumab (Colorectal cancer cohort)

Cabozantinib

  • By mouth (PO) once daily on days 1-28 of every 28 day cycle
  • Dose will be 40mg

Durvalumab

*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle

Drug: Cabozantinib
by mouth
Other Name: multi-tyrosine kinase Inhibitor

Drug: Durvalumab
infusion
Other Name: anti-Programmed cell death protein 1 (PD-L1) inhibitor

Experimental: Cabozantinib plus Durvalumab (Hepatocellular carcinoma cohort)

Cabozantinib

  • By mouth (PO) once daily on days 1-28 of every 28 day cycle
  • Dose will be 40mg

Durvalumab

*Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle

Drug: Cabozantinib
by mouth
Other Name: multi-tyrosine kinase Inhibitor

Drug: Durvalumab
infusion
Other Name: anti-Programmed cell death protein 1 (PD-L1) inhibitor

Experimental: Cabozantinib plus Durvalumab plus Tremelimumab (Hepatocellular carcinoma cohort)

Cabozantinib

  • By mouth (PO) once daily on days 1-28 of every 28 day cycle
  • Dose will be 40mg

Durvalumab *Flat dose of 1500mg intravenous (IV) Infusion on day 1 of every 28 day cycle

Tremelimumab

*Single dose of 300mg intavenous (IV) infusion on day 1 of cycle 1

Drug: Cabozantinib
by mouth
Other Name: multi-tyrosine kinase Inhibitor

Drug: Durvalumab
infusion
Other Name: anti-Programmed cell death protein 1 (PD-L1) inhibitor

Drug: Tremelimumab
infusion
Other Name: Anti-CTLA4 inhibitor




Primary Outcome Measures :
  1. Phase I- Maximum Tolerated Dose (MTD) [ Time Frame: 9 months ]
    Defined as the highest dose studied for which the observed incidence of dose limiting toxicities (DLT) is less than 33%. Determined per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

  2. Phase II- Overall Response Rate (ORR) [ Time Frame: Every 8 weeks for 12 months ]
    Defined as the proportion of participants best response to treatment.


Secondary Outcome Measures :
  1. Proportion of participants with adverse events (AEs). [ Time Frame: 18 months ]
    Determined per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

  2. Overall Benefit Rate (OBR) [ Time Frame: 18 months ]
    Defined as the proportion of patients with overall benefit to therapy. Overall benefit is defined as the best response recorded, (including complete Response (CR), Partial Response (PR), and Stable Disease (SD)), from the start of the treatment until the end of treatment. Determined per Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

  3. Progression Free Survival (PFS) [ Time Frame: 24 months ]
    Defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first. Determined per Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

  4. Overall Survival (OS) [ Time Frame: 24 months ]
    Defined as the time from the start of treatment until death due to any cause. Determined per Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  3. Histologically confirmed diagnosis of any of the following:

    • Gastric or gastroesophageal junction adenocarcinoma
    • Esophageal adenocarcinoma
    • Colorectal adenocarcinoma (CRC)
    • Hepatocellular carcinoma (HCC)
  4. Patients should have advanced (stage 4) or locally unresectable (stage III) disease.
  5. Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
  6. Patients must consent to undergo a required screening/baseline biopsy procedure (and potentially another tumor biopsy at time of disease response and progression) for correlative testing.
  7. Patients with gastric, gastroesophageal, or esophageal adenocarcinoma must show evidence of progression or intolerance to at least one previous standard of care systemic therapy.
  8. Patients with CRC must show evidence of progression or intolerance to at least 2 previous standard of care systemic therapy. Ras wild type patients should fail epidermal growth factor receptor (EGFR) monoclonal antibody (panitumumab or cetuximab) to be eligible.
  9. Patients with HCC must must be treatment naive or show evidence of disease progression or intolerance to at least 1 previous standard of care systemic therapy.
  10. Patients should have known tumor results for microsatellite instability (MSI) or mismatch repair (MMR) proteins. If unknown, analysis will be obtained through local pathology lab using archival tissue if available or the baseline tumor biopsy.
  11. Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior treatments unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  12. Body weight > 66 lbs (30 kg)
  13. Adequate organ and marrow function.
  14. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.
  15. Women of child-bearing potential and men with partners of child-bearing potential must agree to use the highly effective forms of contraception prior to study entry, for the duration of study participation, and for 180 Days post completion of therapy. Men of child-bearing potential must not donate sperm while on this study and for 180 Days after their last study treatment.

Exclusion Criteria:

  1. Prior treatment with a Programmed cell death protein 1 (PD1) or (PD-L1) inhibitor, including durvalumab, or anti PD-L2 (HCC and gastric / esophageal cancer patients with prior exposure to these agents are eligible).
  2. Prior treatment with cabozantinib or other Receptor for hepatocyte growth factor (MET) or Dual MET/ Hepatocyte growth factor (HGF) monoclonal antibodies or MET/HGF tyrosine kinase inhibitors (TKIs), including crizotinib, foretinib, tivantinib, rilotumumab, and onartuzumab.
  3. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.

    • Evidence of tumor invading the GI tract, (Defined as T4 primary tumor in patients with gastric, gastroesophageal and esophageal adenocarcinoma and CRC).
    • Gastric or esophageal varices that are untreated or incompletely treated with bleeding or high risk for bleeding. Subjects treated with adequate endoscopic therapy (according to institutional standards) without any episodes of recurrent GI bleeding requiring transfusion or hospitalization for at least 6 months prior to study entry are eligible.
  4. Evidence of active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.
  5. Inability to swallow tablets.
  6. Uncontrollable ascites or pleural effusion.
  7. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.
  8. Clinically significant hematuria, hematemesis, or hemoptysis of >0.5 tsp (2.5ml) of red blood, or other history of significant bleeding within 12 weeks.

    * Any sign indicative of pulmonary hemorrhage within 3 months.

    * Lesions invading any major blood vessels. HCC subjects with lesions invading the hepatic portal vasculature are eligible.

  9. Any unresolved toxicity CTCAE Grade ≥2 from previous anticancer therapy
  10. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug
  11. Major surgery (eg, Gastrointestinal (GI) surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment.
  12. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses.
  13. History of allogenic organ transplantation.
  14. Active or prior documented autoimmune or inflammatory disorders
  15. History of active primary immunodeficiency
  16. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus. HCC patients with hepatitis B or C infection are allowed per protocol specific criteria.
  17. Receipt of live attenuated vaccine within 30 days prior to the first dose.
  18. Uncontrolled hypertension defined as sustained blood pressure (BP) > 140 millimeter of mercury (mm Hg) systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment.
  19. Stroke, including transient ischemic attack (TIA), myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before first dose. Participants with a diagnosis of deep venous thrombosis (DVT) within 6 months are allowed if stable, asymptomatic, and treated with Low Molecular Weight Heparin (LMWH) for at least 2 weeks before first dose.
  20. Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
  21. Clinically significant disorders that would preclude safe study participation.
  22. History of another primary malignancy except for:

    • Malignancy treated with curative intent/ resection and with no known active disease before the first dose of investigational product (IP) and of low potential risk for recurrence.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated carcinoma in situ without evidence of disease.

24. Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:

a. Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted.

b. Low-dose (prophylactic) low molecular weight heparins (LMWH) are permitted. c. Anticoagulation with therapeutic doses of LMWH is allowed in subjects with no known brain metastases, clinically significant hemorrhage, or complications from a thromboembolic event on the anticoagulation regimen (subjects with HCC must also have a screening platelet count >100,000/μl), and who have been on a stable dose of LMWH for at least 1 week before first dose.

25. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03539822


Contacts
Layout table for location contacts
Contact: KUCC Navigator 913-588-3671 KUCC_Navigation@kumc.edu
Contact: Anwaar Saeed, MD asaeed@kumc.edu

Locations
Layout table for location information
United States, Kansas
University of Kansas Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: KUCC Navigator    913-588-3671    KUCC_Navigation@kumc.edu   
Sponsors and Collaborators
Anwaar Saeed
AstraZeneca
Exelixis
Investigators
Layout table for investigator information
Principal Investigator: Anwaar Saeed, MD The University of Kansas Cancer Center
Layout table for additonal information
Responsible Party: Anwaar Saeed, Associate Professor, University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT03539822    
Other Study ID Numbers: IIT-2017-Cabozant+DurvaGI
First Posted: May 29, 2018    Key Record Dates
Last Update Posted: May 10, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Anwaar Saeed, University of Kansas Medical Center:
Cabozantinib
Durvalumab
Tremelimumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma, Hepatocellular
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Liver Diseases
Durvalumab
Tremelimumab
Immune Checkpoint Inhibitors
Antineoplastic Agents, Immunological
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action